Matinas Biopharma (MTNB) Competitors $1.00 +0.01 (+0.97%) Closing price 04:00 PM EasternExtended Trading$0.99 -0.01 (-1.30%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. VYNE, CING, BLRX, MEIP, AYTU, HOTH, CARM, MRKR, CTXR, and PRPHShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include VYNE Therapeutics (VYNE), Cingulate (CING), BioLineRx (BLRX), MEI Pharma (MEIP), Aytu BioPharma (AYTU), Hoth Therapeutics (HOTH), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors VYNE Therapeutics Cingulate BioLineRx MEI Pharma Aytu BioPharma Hoth Therapeutics Carisma Therapeutics Marker Therapeutics Citius Pharmaceuticals ProPhase Labs VYNE Therapeutics (NASDAQ:VYNE) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends. Which has more volatility & risk, VYNE or MTNB? VYNE Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Which has preferable earnings and valuation, VYNE or MTNB? Matinas Biopharma has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVYNE Therapeutics$605K31.68-$39.83M-$0.99-1.27Matinas BiopharmaN/AN/A-$22.94M-$3.86-0.26 Do insiders & institutionals believe in VYNE or MTNB? 83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are owned by institutional investors. 4.8% of VYNE Therapeutics shares are owned by insiders. Comparatively, 4.6% of Matinas Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is VYNE or MTNB more profitable? Matinas Biopharma has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,974.55%. VYNE Therapeutics' return on equity of -71.89% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets VYNE Therapeutics-6,974.55% -71.89% -58.94% Matinas Biopharma N/A -123.06%-94.28% Does the media favor VYNE or MTNB? In the previous week, VYNE Therapeutics had 2 more articles in the media than Matinas Biopharma. MarketBeat recorded 2 mentions for VYNE Therapeutics and 0 mentions for Matinas Biopharma. VYNE Therapeutics' average media sentiment score of 1.15 beat Matinas Biopharma's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media. Company Overall Sentiment VYNE Therapeutics Positive Matinas Biopharma Neutral Do analysts recommend VYNE or MTNB? VYNE Therapeutics presently has a consensus target price of $6.25, indicating a potential upside of 396.03%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe VYNE Therapeutics is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryVYNE Therapeutics beats Matinas Biopharma on 12 of the 15 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$5.09M$752.17M$5.57B$20.65BDividend YieldN/A4.84%4.23%3.65%P/E Ratio-0.211.4328.6127.29Price / SalesN/A25.51412.0053.17Price / CashN/A19.5636.0222.28Price / Book0.236.608.234.60Net Income-$22.94M-$4.53M$3.23B$995.22M7 Day Performance1.01%1.40%-0.01%-0.80%1 Month Performance7.37%1.30%5.61%3.55%1 Year PerformanceN/A3.42%26.52%7.35% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$1.00+1.0%N/AN/A$5.09MN/A-0.2130VYNEVYNE Therapeutics2.9657 of 5 stars$1.33-6.3%$6.25+369.9%-42.7%$20.23M$500K-1.3430Positive NewsHigh Trading VolumeCINGCingulate3.2889 of 5 stars$4.73+8.7%$26.00+449.7%+1,032.8%$20.08MN/A-0.5620BLRXBioLineRx2.6208 of 5 stars$4.70flat$26.00+453.2%-85.1%$20.04M$22.34M-0.5340Gap UpMEIPMEI Pharma2.2034 of 5 stars$2.94+9.3%N/A+7.9%$19.58MN/A-0.62100Positive NewsHigh Trading VolumeAYTUAytu BioPharma4.2732 of 5 stars$2.15-1.4%$10.00+365.1%-23.0%$19.31M$81M-2.99160Positive NewsHOTHHoth Therapeutics3.2725 of 5 stars$1.43-0.7%$4.00+179.7%+52.3%$18.89MN/A-1.254Positive NewsCARMCarisma Therapeutics3.0064 of 5 stars$0.45+12.7%$1.93+327.0%-67.5%$18.84M$19.63M-0.2920MRKRMarker Therapeutics4.4872 of 5 stars$1.58-7.6%$13.17+733.3%-71.8%$17.87M$6.59M-1.1960CTXRCitius Pharmaceuticals3.0184 of 5 stars$1.67+7.1%$53.00+3,073.7%-91.5%$17.75MN/A0.0020News CoveragePRPHProPhase Labs0.5359 of 5 stars$0.43+0.4%N/A-87.1%$17.66M$5.85M-0.34130Positive NewsGap Down Related Companies and Tools Related Companies VYNE Alternatives CING Alternatives BLRX Alternatives MEIP Alternatives AYTU Alternatives HOTH Alternatives CARM Alternatives MRKR Alternatives CTXR Alternatives PRPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
